skip to main content
UK Health Security Agency

KARPAS-1718

KARPAS-1718

Catalogue No.

08072401

Cell Line Name

KARPAS-1718

Cell Line Description

KARPAS 1718 is derived from the peripheral blood of a patient diagnosed with transformed splenic lymphoma with villous lymphocytes

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Tissue of Origin

Spleen (Splenic Lymphoma)

Morphology

Single round to polymorphic cells growing in suspension

DNA profile (STR Profile)

Amelogenin: X,Y
CSF1PO: 11,13
D5S818: 11,12
D7S820: 8
D13S317: 8,13
D16S539: 11,13
TH01: 6
TPOX: 8,11
vWA: 14

Applications

Oncology research

Disease

Neuroblastoma/Glioma Hybrid

Culture Conditions

Cell Type

Haematopoietic

Subculture Routine

Maintain cultures between 3-9 x 10⁵ cells/ml; 5% CO₂; 37°C. Thaw ampoule and perform a cell count, spin out the DMSO and resuspend in an appropriate volume of media to give a cell concentration of 4-5 x 10⁵ cells/ml. Viability may be poor on resuscitation and may decrease further within the first 48 hours, the culture may appear non-viable at this time. Clusters of cells will eventually appear but this could take 1-2 weeks, during this time large media changes are not recommended. It may take 2-3 weeks for vigorous growth to be established. At subculture perform a cell count and maintain cultures between 3-9 x 10⁵ cells/ml, 5% CO₂, 37°c. For cryopreservation of KARPAS 1718, freeze at approximately 2 x 10⁷ cells/ml in 90% FBS + 10% DMSO.

Culture Medium

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)

Growth Mode

Suspension

Additional Info

Depositor

Dr Abraham Karpas, Department of Haematology, MRC Centre, Hills Road, Cambridge, UK

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Ota et al., 2004 Identification and Characterization of a Novel Gene, C13orf25, as a Target for 13q31-q32 Amplification in Malignant Lymphoma. Cancer Research 64: 3087-3095. (PMID: 15126345).

Bibliography

Sonoki et al., 2004 Rapid Amplification of Immunoglobulin Heavy Chain Switch (IGHS) Translocation Breakpoints Using Long-distance Inverse PCR. Leukemia 18: 2026-2031(PMID: 15496980). Martinez-Climent et al., 2003 Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma. Leuk. Lymphoma 44: 459-64. (PMID: 12688315)

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: KARPAS-1718 (ECACC 08072401).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.